Human IL-12 Protein, premium grade
分子別名(Synonym)
IL12,p70,Interleukin-12
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-12 Protein, premium grade (IL2-H5210) is expressed from human 293 cells (HEK293). It contains AA Ile 23 - Ser 328 & Arg 23 - Ser 219 (Accession # P29460-1 & P29459-1).
Predicted N-terminus: Ile 23
專為臨床前階段設(shè)計的premium級重組人IL-12蛋白(IL2-H5210)與GMP級重組人IL-12(GMP-L12H23)具有相同的活性和性能,能夠?qū)崿F(xiàn)從臨床前發(fā)展到臨床階段的無縫過渡。在原材料安全不是首要任務(wù)的早期開發(fā)階段,premium級產(chǎn)品為GMP級產(chǎn)品提供了一種經(jīng)濟高效的替代品。通過在早期開發(fā)階段使用高級產(chǎn)品,您可以輕松過渡到臨床和商業(yè)階段,而無需重新驗證原材料和修改生產(chǎn)流程。
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries no "tag".
The protein has a calculated MW of 58.9 kDa. The protein migrates as 76 kDa±3 kDa under reducing (R) condition, and 69 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
宿主蛋白殘留(Host Cell Protein)
<0.5 ng/μg of protein tested by ELISA.
宿主核酸殘留(Host Cell DNA)
<0.02 ng/μg of protein tested by qPCR.
無菌(Sterility)
Negative
支原體(Mycoplasma)
Negative.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
白細(xì)胞介素12(IL-12)也稱為p70,是一種由樹突狀細(xì)胞、巨噬細(xì)胞和人類B淋巴細(xì)胞樣細(xì)胞(NC-37)響應(yīng)抗原刺激而自然產(chǎn)生的白細(xì)胞介質(zhì)。IL-12是一種異二聚體細(xì)胞因子,含有IL-12A(p35)和IL-12B(p40)。IL-12參與將幼稚T細(xì)胞分化為Th1細(xì)胞。它被稱為T細(xì)胞刺激因子,可以刺激T細(xì)胞的生長和功能。它刺激T細(xì)胞和NK細(xì)胞產(chǎn)生IFN-γ和TNF-α,并減少IL-4介導(dǎo)的對IFN-γ的抑制。IL-12在自然殺傷細(xì)胞和T淋巴細(xì)胞的活性中起著重要作用。IL-12還具有抗血管生成活性,這意味著它可以阻斷新血管的形成。
關(guān)鍵字: IL-12;IL-12蛋白;IL-12重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。